Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
PF-08046037 joins PF-08046054 in clinical development.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
